Vitamin D3 clinical brief
Vitamin D3
Dossier liveCompound
Publication state
Dossier live
Published from structured dossier data. Authored scoring and decision-tool promotion can be layered in later.
What it is for
Deficiency prevention and adequacy maintenance in adults with limited sun exposure or confirmed insufficiency
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Human linked
HOMA-IR
Glycemic control
Decrease
Grade A
HbA1c
Glycemic control
Decrease
Grade A
Fasting glucose
Glycemic control
Decrease
Grade A
Top caution
Drug interaction
Therapeutic potential in CYP24A1-loss-of-function hypercalcemia and sarcoidosis-related hypercalcemia; interaction relevant when initiating/stopping ketoconazole in patients on vitamin D supplementation
Dossier status
Dossier live
Published from dossier data; authored scoring and decision-tool promotion can be layered in later.
Meta-analyses
169
Pooled human evidence
RCTs
521
Randomized clinical trials
Tracked studies
925
Studies currently mapped to this dossier
Executive summary
Immediate brief
Vitamin D3 is a compound with its clearest current use in Deficiency prevention and adequacy maintenance in adults with limited sun exposure or confirmed insufficiency.
This live dossier is anchored by 925 tracked studies, 169 meta-analyses, 521 RCTs and the clearest tracked movement in HOMA-IR, HbA1c, Fasting glucose.
Vitamin D3 has an exceptionally wide therapeutic window compared to virtually all drugs. Therapeutic potential in CYP24A1-loss-of-function hypercalcemia and sarcoidosis-related hypercalcemia; interaction relevant when initiating/stopping ketoconazole in patients on vitamin D supplementation
Anchor decision
Deficiency prevention and adequacy maintenance in adults with limited sun exposure or confirmed insufficiency
Best current human use case
Publication
Dossier live
Published from structured dossier data; authored scoring and decision-tool promotion can be layered in later.
Read next
Drug interaction
Pressure-test the lead caution before acting.
Reading guide
How to use this brief
1. Orient
Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.
2. Pressure-test
Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.
3. Operationalize
Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.
Major warning
XPregnancy at pharmacological doses (>4000 IU/day)
Supplementation dosing and deficiency screening calibrated solely to total 25OHD thresholds may over-supplement Black Americans.
Overview
Clinical posture
Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.
Primary signal
Mechanism summary
Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.
Co-primary
Safety summary
These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.
Supporting context
Evidence scope
Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.
Generalizability
ReviewA disproportionate fraction of vitamin D3 RCTs - particularly glycemic, lipid, and inflammatory endpoints - originate from Iran, China, and Middle Eastern countries where baseline 25OHD is typically lower due to sun avoidance, darker skin pigmentation, and dietary practices.
Evidence scope
ReviewBolus vitamin D supplementation (>=100,000 IU monthly or quarterly) produces discordant outcomes vs daily/weekly dosing across multiple endpoints.
Generalizability
ReviewMeta-analyses consistently show that supplementation benefits are concentrated in deficient individuals (25OHD <50 nmol/L), with null or minimal effects in replete individuals (>75 nmol/L).
Evidence scope
ReviewCKD stages 3-5 attenuate renal CYP27B1 activity, reducing conversion of 25OHD to active 1,25(OH)2D despite adequate 25OHD repletion.
Synergies
Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.
Vitamin D3 + calcium (elemental)
Pooled meta-analyses (Bischoff-Ferrari 2004/2005, n>5000 elderly) demonstrate that D3 + calcium reduces hip fracture risk by 18-27% (NNT ~45-60 for 3-4 years) in elderly populations - substantially greater than D3 alone (~10% non-significant in most analyses) or calcium alone.
Vitamin D3 + magnesium
Magnesium insufficiency is a clinically important but underrecognised cause of poor D3 supplementation response.
Research unknowns
These are the open questions that still keep the compound from reading like a closed case.